Sclerotherapy for lower limb telangiectasias.

摘要: Background Sclerotherapy has been used in clinical practice for centuries, but there is still no consensus about which, if any, sclerosing agent provides the best results. Objectives To assess effectiveness and safety of agents treatment telangiectasias lower limbs. Search methods The Cochrane Peripheral Vascular Diseases (PVD) Group searched their Specialised Register (last 26 May 2011) CENTRAL (2011, Issue 2). We references within identified studies from Cited References Web Science. contacted study authors pharmaceutical companies. There were language restrictions. Selection criteria We included randomised or quasi-randomised controlled trials on comparing sclerotherapy with a normal saline placebo, an alternative regimen. Data collection analysis Both determined which to include, extracted data rated risk bias. One author (LS) companies analysed results. Main results Ten involving 484 patients included. was evidence suggesting superior efficacy any one sclerosant over another, superiority placebo. The did not suggest increase patient satisfaction versus that less satisfied placebo. There some polidocanol (POL) more likely cause adverse reactions at concentration 1% compared concentrations hypertonic saline, sodium tetradecyl sulfate (STS) POL 0.5%. There STS painful than POL, heparsal (20% mixed heparin 100 units/mL) placebo. Evidence suggested (HS) POL. The suitable meta-analysis. Authors' conclusions The limbs, studied showed However, amount available this field small overall methodological quality research poor, as reporting. More needed determine optimal agent(s) ideal dosing achieve results maximize satisfaction. Future efforts should incorporate demographic symptom measures allow comparison findings observational studies, thereby aiding assessment how various groups respond treatment.